Question 1

Is it safe to prescribe an SSRI during pregnancy, and when does untreated anxiety become the bigger risk?

Accepted Answer

Untreated antenatal anxiety carries quantified obstetric risks: preterm birth OR 1.54, low birth weight OR 1.80, reduced fetal head circumference (Grigoriadis 2018). ACOG 2023 establishes SSRIs as first-line for moderate-severe perinatal anxiety. Sertraline has no confirmed teratogenic associations (Reefhuis 2015 BMJ). Paroxetine carries FDA warning for specific cardiac defects (OR ~2.4 RVOTO) but absolute risk remains <1%. PPHN risk with late-pregnancy SSRI: baseline 0.15% rises to 0.3-0.7%. NAS occurs in ~11% of exposed neonates (Cornet et al., 2024), typically mild and self-limiting within 48-72 hours. Never advise abrupt SSRI discontinuation upon discovering pregnancy.

Question 2

What does the data show about SSRI teratogenicity?

Accepted Answer

Untreated antenatal anxiety carries quantified obstetric risks: preterm birth OR 1.54, low birth weight OR 1.80, reduced fetal head circumference (Grigoriadis 2018). ACOG 2023 establishes SSRIs as first-line for moderate-severe perinatal anxiety. Sertraline has no confirmed teratogenic associations (Reefhuis 2015 BMJ). Paroxetine carries FDA warning for specific cardiac defects (OR ~2.4 RVOTO) but absolute risk remains <1%. PPHN risk with late-pregnancy SSRI: baseline 0.15% rises to 0.3-0.7%. NAS occurs in ~11% of exposed neonates (Cornet et al., 2024), typically mild and self-limiting within 48-72 hours. Never advise abrupt SSRI discontinuation upon discovering pregnancy.

Question 3

Is paroxetine's cardiac defect risk clinically meaningful?

Accepted Answer

Untreated antenatal anxiety carries quantified obstetric risks: preterm birth OR 1.54, low birth weight OR 1.80, reduced fetal head circumference (Grigoriadis 2018). ACOG 2023 establishes SSRIs as first-line for moderate-severe perinatal anxiety. Sertraline has no confirmed teratogenic associations (Reefhuis 2015 BMJ). Paroxetine carries FDA warning for specific cardiac defects (OR ~2.4 RVOTO) but absolute risk remains <1%. PPHN risk with late-pregnancy SSRI: baseline 0.15% rises to 0.3-0.7%. NAS occurs in ~11% of exposed neonates (Cornet et al., 2024), typically mild and self-limiting within 48-72 hours. Never advise abrupt SSRI discontinuation upon discovering pregnancy.

Question 4

What are the risks of untreated anxiety in pregnancy?

Accepted Answer

Untreated antenatal anxiety carries quantified obstetric risks: preterm birth OR 1.54, low birth weight OR 1.80, reduced fetal head circumference (Grigoriadis 2018). ACOG 2023 establishes SSRIs as first-line for moderate-severe perinatal anxiety. Sertraline has no confirmed teratogenic associations (Reefhuis 2015 BMJ). Paroxetine carries FDA warning for specific cardiac defects (OR ~2.4 RVOTO) but absolute risk remains <1%. PPHN risk with late-pregnancy SSRI: baseline 0.15% rises to 0.3-0.7%. NAS occurs in ~11% of exposed neonates (Cornet et al., 2024), typically mild and self-limiting within 48-72 hours. Never advise abrupt SSRI discontinuation upon discovering pregnancy.

Question 5

Which SSRIs are safe for breastfeeding?

Accepted Answer

Untreated antenatal anxiety carries quantified obstetric risks: preterm birth OR 1.54, low birth weight OR 1.80, reduced fetal head circumference (Grigoriadis 2018). ACOG 2023 establishes SSRIs as first-line for moderate-severe perinatal anxiety. Sertraline has no confirmed teratogenic associations (Reefhuis 2015 BMJ). Paroxetine carries FDA warning for specific cardiac defects (OR ~2.4 RVOTO) but absolute risk remains <1%. PPHN risk with late-pregnancy SSRI: baseline 0.15% rises to 0.3-0.7%. NAS occurs in ~11% of exposed neonates (Cornet et al., 2024), typically mild and self-limiting within 48-72 hours. Never advise abrupt SSRI discontinuation upon discovering pregnancy.

PsychHQ

SSRI Safety in Pregnancy: Absolute Risk Numbers and When Untreated Anxiety Becomes the Bigger Threat